Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

64.21 +0.58 (+0.91%)
Streaming Delayed Price Updated: 9:45 AM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Present at Upcoming Investor Conferences in March
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Hits 19-Month High Amid Trading Halts ↗
Via Stocktwits
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside ↗
Via Stocktwits
News headline image
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗
Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings. 
Via Stocktwits
News headline image
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Inc (NASDAQ:SPRB) Reports Q3 2025 Results, Secures $50M Financing and Breakthrough Therapy Designation ↗
Spruce Biosciences reports Q3 2025 results, secures $50M financing and Breakthrough Therapy Designation for its lead drug candidate. 
Via Chartmill
News headline image
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Top stock movements in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Tuesday's session: gap up and gap down stocks ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why ↗
Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Syndrome Type B. 
Via Benzinga
News headline image
Why Spruce Biosciences Just Skyrocketed More Than 1,600% ↗
The company is working on a treatment for a rare, genetic disease. 
Via Investor's Business Daily
News headline image
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Spruce Biosciences Stock Is Soaring Today: Here's Why ↗
Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory update about one of its therapy treatments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.